Significant advancements in gene therapy, Growing DMD pipeline, government initiatives, and strategic collaborations to drive DMD market in future says RNCOS.
According to a new research report by RNCOS entitled, “Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Forecast to 2022”, the global market for DMD therapeutics is estimated to reach approximately US$ 27 Billion by 2022, growing at a CAGR of around 160.8% over 2016-2022. The DMD therapeutics market is majorly in the research phase from which most of its revenue is generated. Consequently, it has very few marketed products. The market presently consists of only three DMD drugs namely, Translarna, Emflaza, and EXONDYS 51. Also, these drugs are being incorporated with different therapeutic approaches, such as, exon skipping, mutation suppression, and steroid therapy.
With the significant advancement in the therapeutic strategies, many players are entering into the pool of DMD research and development. Further, in order to cash in on this new technology, companies and non-industry participants are indulging in strategic moves such as collaborations, mergers and acquisitions. Most of these moves are being made in order to combine technologies and capabilities from other companies/research institutes with inherent ones for the development of novel DMD drugs. Taking into consideration the present scenario and growth opportunities, DMD therapeutics market is anticipated to witness an impressive progression. The companies operating in the DMD therapeutics market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms, which are aiding them to develop new products.
Research Analysis & Highlights
This report is spread over 100 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Duchenne Muscular Dystrophy Therapeutics market. The report provides the sales of major marketed DMD products. The report also provides detailed pipeline analysis of Duchenne Muscular Dystrophy market. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the DMD market, such as phases, geographies, and key players. The segment also covers the list of the key ongoing clinical trials along with their clinical phases, and geography.
The report prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, therapeutic approach, and geographical performance. According to the research, mutation suppression (stop codon read-through) is the most promising and widely used approach by the companies. Moreover, the report provides a brief summary of the recent trends that may have an impact on the future industry performance. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over in DMD market have been provided.
Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global Duchenne Muscular Dystrophy Therapeutics market. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments.
Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
Some of the key highlights of the report include the following:
• Marketed DMD products
• Strategies adopted by players to advance in the DMD therapeutics market
• Europe showing dynamic research and development for gene therapy.
• Growing clinical trials for DMD worldwide.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM909.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm